These approaches can be several magnitudes more sensitive compared to the cancer patient IGF-I/IGF-II high blood ratio currently reported as the discriminating metabolic hallmark for paraneoplastic hypoglycemia-associated cancers [28]. This evidence concerns the gene IGF1 and cancer.